The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications

Review

关键词: CLOSTRIDIUM-DIFFICILE INFECTION;    INFLAMMATORY-BOWEL-DISEASE;    ACTIVE ULCERATIVE-COLITIS;    INTESTINAL MICROBIOTA;    INSULIN SENSITIVITY;    CONTROLLED-TRIAL;    GUT MICROBIOTA;    UNITED-STATES;    HOST-DISEASE;    DOUBLE-BLIND;   

DOI  :  10.1016/S0140-6736(19)31266-8

来源: SCIE

【 摘 要 】

Developments in high-throughput microbial genomic sequencing and other systems biology techniques have given novel insight into the potential contribution of the gut microbiota to health and disease. As a result, an increasing number of diseases have been characterised by distinctive changes in the composition and functionality of the gut microbiota; however, whether such changes are cause, consequence, or incidental to the disease in question remains largely uncertain. Restoration of the gut microbiota to a premorbid state is a key novel therapeutic approach of interest, and faecal microbiota transplantation-the transfer of prescreened stool from healthy donors into the gastrointestinal tract of patients-is gaining increasing importance in both the clinical and research settings. At present, faecal microbiota transplantation is only recommended in the treatment of recurrent Clostridioides difficile infection, although a large number of trials are ongoing worldwide exploring other potential therapeutic indications.

【 授权许可】

Free